Jinan Babio Biotechnology Co., Ltd.

Founded in 2003, Jinan Babio Biotechnology Co., Ltd. is a professional high-tech enterprise which concentrates on the R&D, manufacturing and selling of in vitro diagnostic reagent. The company was successfully listed on the NEEQ (National Equities Exchange and Quotations) in 2014 (security name: Baibo Biotechnology, stock code: 830774). The company has established a strict quality management system and passed ISO9001:2008 and ISO13485:2003 international quality system certifications. The company has internationally advanced fully automatic production equipment and standard purification workshop of pharmaceutical grade. Baibo has strong biotechnology power, and currently has more than 72 independent intellectual property rights, it undertakes a number of national scientific research projects and has 91 medical device registration certificates approved by CFDA. The company's products mainly involve virus sampling, rapid detection kits, microbial detection reagents, POCT detection reagents, biochemical diagnostic reagents, diagnostic equipment and so on. The Covid-19 pandemic outbroke all over the world in 2020, Baibo has been actively involved in the R&D and manufacturing of Covid-19 sampling and testing reagents. Currently, the company's products of virus transport media, nasal/oral sampling swabs, Covid-19 antigen and IGG/IGM rapid detection kits have been sold to over 56 countries, and the products' quality has been recognized by the medical institutions and laboratories of various countries, the company has made a contribution for fighting against the Covid-19 epidemic for people around the world. In the future, Babio will be committed to providing better technology and services, and continue to struggle for the human health